Recursion Pharmaceuticals (RXRX): CEO sold, ~$2.64M

~$2.64M
Approx. value · 500K sh @ $5.28: 1M
Holds after · shares reported

Traded: Aug 11, 2025
Filed: Aug 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Aug 11, 2025 · this disclosureInsiderCEO sold ~$2.64M of RXRX shares in the open market

What came next

Aug 11, 2025Insider · 1 personInsiders: 2 sales (~$622K)
Aug 18, 2025InsiderDirector sold ~$202K of RXRX shares in the open market
Aug 26, 2025InsiderCEO sold ~$484K of RXRX shares in the open market
Sep 10, 2025InsiderCEO sold ~$471K of RXRX shares in the open market
Sep 25, 2025InsiderCEO sold ~$476K of RXRX shares in the open market
Nov 4, 2025Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On November 4, 2025, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) appointed Najat Khan, Ph.D., the Company’s Chief Research and Development Officer and Chief Commercial Officer, as the Company’s Chief Executive Officer and President, and appointed Christopher Gibson, Ph.D., the Company’s Chief Executive Officer and President, as Chair of the Board, both effective as of…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Recursion Pharmaceuticals

For Recursion Pharmaceuticals, OQRO holds 4 insider filings (SEC Form 4 or Form 144) and 4 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RXRX page.

Other recent filings by Christopher Gibson, Chief Executive Officer

The full history of Christopher Gibson, Chief Executive Officer is on the profile page.

Other disclosures at Recursion Pharmaceuticals

Everything OQRO holds on this company is on its RXRX page.

Recursion Pharmaceuticals (RXRX)CEO sold ~$2.64M